8. 4g MgSO4 IV push over 20 min
Combined IM and IV regimen
• Loading dose: (total dose 9gm)
And
2.5g (5ml of 50%) MgSO4 IM into each buttock
9. 4g MgSO4 IV push over 20 min
Add 8ml 50% MgSO4 (4g) in 100ml 0.9% saline or
5% glucose administer IV over 20min.
OR, if you have syringe-driver pump
Add 8ml 50% MgSO4 (4g) to 12ml 0.9% saline or 5%
glucose and infuse IV over 20min at 60ml.h-1
2.5g (5ml of 50%) MgSO4 IM into each buttock
10. Combined IM and IV regimen
Maintenance dose:
❑ 2.5 g (5ml- 50%) MgSO4 IM 4 hourly using
alternate buttocks.
❑ Continue for 24 hours after last convulsion or
delivery.
11. For Recurrent Seizures
❖ Administer a further 2g MgSO4 IV.
❖ Draw 4ml (2g) of 50% MgSO4 into 10ml syringe
and add 6ml 0.9% saline or 5% glucose.
➢ inject over 2min (5ml.min-1)
❖ If convulsions still continue, consider diazepam
5mg or lorazepam 1mg (IV or IM).
❖ Be aware of risk of respiratory depression.
Combined IM and IV regimen
12. Intravenous IV regimen
Loading Dose:
o Fill a paediatric infusion burette set with 22 ml 5%
dextrose, Add 8 ml of 50 % MgSO4 (4g) .
o Administer the 20ml solution at 60ml/hr.
o So the total dose will run over 30 min.
13. Maintenance Dose:
➢ Fill a paediatric infusion burette with 112ml 5%
glucose, add 8ml 50% MgSO4 (4g) making 120ml
solution
✓Administer at 30ml.h-1, the total will run over 4
hours (1g.h-1)
➢ Repeat the same management every 4hr for at
least 24 hours after the last convulsion or delivery
Intravenous IV regimen
14. For Recurrent Seizures
❖ Administer a second loading dose or increase
the infusion to 1.5 or 2g.h-1
Intravenous IV regimen
15. Each ampoule: 1gm/10ml/over 5min
4 ampoule is 4 gm/40ml/over 20 min
10%MgSO4
1 gm (10ml) over 5 min /hourly
Or
4gm (40ml) infusion pump at
10ml/hour/4hour
16. ❖Vasodilatation effect:
❖• Feeling of warmth
❖• Lethargy
❖• Facial flushing
❖• hypotension
Other side effects:
❑ Nausea, Vomiting, sweating
❑ Diminished reflexes
❑ Confusion
❑ Intense thirst
17. MgSO4 Toxicity
➢ Loss of patellar reflexes.
➢ Respiratory paralysis.
➢ Heart block.
➢ Collapse of circulatory system.
➢ Death.
18. Monitoring of patients on MgOS4
narrow therapeutic index (4-7mEq/l)
3 R parameters
Respiratory rate should be 16 cycle per
min or more
19. Monitoring of patients on MgOS4
Renal output during
treatment should be at least 30
ml/hr, half the dose of the mag
should be given if less than 100
ml /4 hours.
Reflex of deep tendon
should be present prior to
initiating therapy.
21. MgSO4 Toxicity Antidote
❑ Calcium gluconate: 1g (10ml of 10% IV
over 10 minutes. Repeat doses may be
necessary).
❑ Calcium chloride can also be used
500 mg of 10% calcium chloride IV given
over 5-10 minutes.
22.
23. ❑ loading dose of 4gm of 50% IV MgSO4 diluted in 20cc of
5% of dextrose over 10-15 minutes, simultaneously 4gm
of MgSO4. Intramuscularly, 2gm on each buttock ..If the
convulsions are not controlled even after 30 minutes of
giving single dose MgSO4, then it is switched over to
other regimes like low dose magnesium sulphate and
Phenytoin regime.
24. ❑ The convulsions were controlled in 75% of
women. Recurrence of convulsions occurred in
25% of women after receiving the single dose
MgSO4 regime.
❑ Conclusions: Hence the single dose MgSO4 is
safe and effective in controlling convulsions.
25. Methods: A prospective randomized controlled study of
magnesium sulphate therapy in women with severe preeclampsia
was conducted with 50 patients each in control and study group.
The control group received 24 hours of postpartum magnesium
sulphate therapy and the study group received for 4 hours or one
intramuscular dose in postpartum period.
Conclusions: In patients with severe preeclampsia shorter duration (4
hours or one dose) of postpartum magnesium sulphate therapy, is as
effective as the standard 24 hours of postpartum therapy.
26.
27. Conclusion: Magnesium sulfate combined with Nifedipine in
the treatment of PIHS has a significant effect, which can
effectively control edema, blood pressure, proteinuria and
protect kidney. It is worth clinical promotion.
30. Despite improvements in perinatal care, preterm birth still
occurs regularly and the associated brain injury and
adverse neurological outcomes remain a persistent
challenge. Antenatal MgSO4 administration is an
intervention with demonstrated neuroprotective effects for
preterm births before 32 weeks of gestation. Owing to its
biological properties, including its action as an N-methyl-d-
aspartate receptor blocker and its anti-inflammatory
effects, magnesium sulphate is a good candidate for
neuroprotection.
31. In hypoxia models, including hypoxia-ischemia,
inflammation, and excitotoxicity in various species
(mice, rats, pigs), magnesium sulfate
preconditioning decreased the induced lesions’
sizes and inflammatory cytokine levels, prevented
cell death, and improved long-term behavior. In
humans, some observational studies have
demonstrated reduced risks of cerebral palsy after
antenatal magnesium sulfate therapy.
32. Conclusions:
MgSO4 is a safe and effective molecule that plays a key role
in protecting the immature brain. It is a cost-effective,
feasible, efficient, and safe intervention that contributes to
the improvement of neurological outcomes. While MgSO4
has not been found to significantly improve cognition and
behavior outcomes at school age, it prevents cerebral
palsy at 2 years. Its use is now recommended by several
pediatric and obstetrical societies, as well as the World
Health Organization (strong recommendation based on
moderate-quality evidence) for women at risk of imminent
preterm birth before 32 WG.
33. Conclusions—Antenatal magnesium sulfate exposure is
independently associated with a decreased risk of MRI-
detected cerebellar hemorrhage in premature newborns,
which could explain some of the reported neuroprotective
effects of magnesium sulfate.
34. Conclusions
Antenatal magnesium sulphate given prior to preterm birth
for fetal neuroprotection prevents CP and reduces the
combined risk of fetal/infant death or CP. Benefit is seen
regardless of the reason for preterm birth, with similar
effects across a range of preterm gestational ages and
different treatment regimens. Widespread adoption
worldwide of this relatively inexpensive, easy-to-administer
treatment would lead to important global health benefits for
infants born preterm.
35. Low doses:
4 g loading dose ± 1 g/h maintenance dose for 12 h,
16 g maximum total dose).
High doses:
6 g loading dose + 2 g/h maintenance dose during
24 h, maximum total dose received: 54 g).
.